Immunovant (IMVT) stock was on the rise after the clinical-stage biotech company reported wider losses in its latest earnings update. The company posted a net loss of $147.9 million, or 73 cents per share, for the first quarter of 2026. That compares to a net loss of $106.4 million, or 64 cents per share, during the same period last year. The company’s per-share loss also missed Wall Street’s estimate of 59 cents. Even so, investors may be paying closer attention to the company’s pipeline progress than the quarterly loss itself.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Immunovant also shared fresh data from its IMVT-1402 trial in difficult-to-treat rheumatoid arthritis. Preliminary Week 16 results showed ACR20 response rates of 72.7%, ACR50 response rates of 54.5%, and ACR70 response rates of 35.8%. Those results appear to support growing optimism around the company’s lead program. In addition, Immunovant said that more updates from the IMVT-1402 program are expected later this year. This includes topline data from its proof-of-concept trial in cutaneous lupus erythematosus.
However, not all of the company’s recent updates were positive. In April 2026, Immunovant revealed that two Phase 3 studies of batoclimab in thyroid eye disease failed to meet their primary endpoints. As a result, the company ended development of batoclimab across all indications and shifted its full focus to IMVT-1402.
Immunovant Stock Movement Today
Immunovant stock was up 31.04% on Wednesday, extending a 36.62% year-to-date rally. The stock has also climbed 82.44% over the past 12 months.
Today’s report also resulted in increased trading activity. This saw some 10.24 million shares of IMVT stock change hands, compared to a three-month average daily trading volume of about 1.52 million shares.
Is Immunovant Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for Immunovant is Strong Buy, based on seven Buy and two Hold ratings over the past three months. With that comes an average IMVT stock price of $43.78, which represents a potential 26.34% upside for the shares.
